Sermorelin plus a GHRP.
The older version of the growth hormone pairing, with the same sound rationale and a less clean side-effect profile.
Evidence check · reviewed June 1, 2026
As with the newer GH stack, the rationale is that a GHRH analog and a ghrelin mimetic engage two separate receptors and together produce a larger growth hormone release than either alone.
What the evidence actually shows.
This pairing predates the currently more popular combination and rests on identical pharmacology: two independent receptors, both raising GH, larger combined effect. That mechanistic claim is as sound here as it is there.
The component that differs meaningfully is the ghrelin mimetic. The older GHRPs are less selective than the newer alternatives, which matters practically rather than theoretically. They raise cortisol and prolactin alongside growth hormone, and they stimulate appetite, sometimes substantially. Whether appetite stimulation is a side effect or the point depends entirely on what someone is trying to do.
Sermorelin has an unusual regulatory history worth knowing. It previously held FDA approval and was withdrawn from the US market for commercial rather than safety reasons, which is a genuinely different situation from a compound that was never approved or one pulled over a safety signal. Its current availability is largely through compounding.
The outcome evidence problem is unchanged from the newer stack. GH rises measurably. Whether that produces the body composition or recovery results people want has not been established in controlled trials for this combination, and a longer history of use is not the same thing as an evidence base.
Same mechanism and same evidence gap as the newer GH pairing, with a less selective ghrelin component that also raises cortisol and prolactin and stimulates appetite.
FAQ.
How does this differ from CJC-1295 with ipamorelin?
The rationale is identical. The difference is selectivity: the older GHRPs also raise cortisol and prolactin and stimulate appetite noticeably, where ipamorelin was specifically designed to avoid that.
Why is sermorelin no longer FDA-approved?
The approved product was withdrawn from the US market for commercial reasons rather than safety findings. That is a different situation from a compound that failed on safety or was never approved.
Cite this page
PepCue. “Sermorelin plus GHRP stacks: the evidence assessed.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/stacks/sermorelin-ghrp.